Omalizumab + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Persistent Allergic Asthma
Conditions
Persistent Allergic Asthma
Trial Timeline
Mar 1, 2009 → Mar 1, 2010
NCT ID
NCT00870584About Omalizumab + Placebo
Omalizumab + Placebo is a approved stage product being developed by Novartis for Persistent Allergic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00870584. Target conditions include Persistent Allergic Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03369704 | Phase 3 | Completed |
| NCT03328897 | Phase 3 | Completed |
| NCT01723072 | Phase 3 | Completed |
| NCT01202903 | Phase 3 | Completed |
| NCT01007149 | Phase 3 | Completed |
| NCT00870584 | Approved | Completed |
| NCT00657891 | Approved | Completed |
| NCT00454051 | Approved | Completed |
| NCT01393340 | Phase 2 | Completed |
| NCT00123630 | Phase 2 | Completed |
Competing Products
20 competing products in Persistent Allergic Asthma